

Chlamydia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CA2F683F8B8AEN.html>

Date: June 2022

Pages: 67

Price: US\$ 2,000.00 (Single User License)

ID: CA2F683F8B8AEN

Abstracts

Chlamydia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections – Drugs In Development, 2022, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Chlamydia Infections – Overview

Chlamydia Infections – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chlamydia Infections – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chlamydia Infections – Companies Involved in Therapeutics Development

Chlamydia Infections – Drug Profiles

Chlamydia Infections – Dormant Projects

Chlamydia Infections – Product Development Milestones

Featured News & Press Releases

Mar 31, 2022: Evofem presents positive encore data in sexually transmitted infections impacting women at the 2022 Academy of Managed Care Pharmacy Annual Meeting

Mar 04, 2022: Evofem completes enrollment in EVOGUARD Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women

Feb 09, 2022: FDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences

Jan 04, 2022: Evofem Biosciences to present at H.C. Wainwright BioConnect Conference

Dec 21, 2021: Eurocine Vaccines resolves on scientific advice with the Swedish Medical Products Agency ahead of clinical trial application

Dec 01, 2021: Eurocine Vaccines Chlamydia vaccine candidate elicits both antibody and T cell responses

Nov 30, 2021: Evofem Biosciences announces successful type C meeting with FDA for STI prevention product candidate

May 17, 2021: New data on EVO100 for the prevention of chlamydia and gonorrhea in women to be presented at ISPOR 2021

Mar 31, 2021: Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia

Mar 16, 2021: Evofem Biosciences announces publication in American Journal of Obstetrics and Gynecology of AMPREVENCE study of EVO100 for chlamydia and gonorrhea prevention

Feb 25, 2021: Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate

Dec 30, 2020: Eurocine Vaccines advances the development of commercial manufacturing method and updates time plan

Dec 30, 2020: Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate

Dec 22, 2020: Evofem Biosciences to participate in Medicaid National Drug Rebate Program for Phexxi effective January 1, 2021

Dec 21, 2020: Evofem Biosciences to present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Chlamydia Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chlamydia Infections – Pipeline by Abera Bioscience AB, 2022
Chlamydia Infections – Pipeline by Abivax SA, 2022
Chlamydia Infections – Pipeline by Aeterna Zentaris Inc, 2022
Chlamydia Infections – Pipeline by BlueWillow Biologics Inc, 2022
Chlamydia Infections – Pipeline by Erganeo, 2022
Chlamydia Infections – Pipeline by Eurocine Vaccines AB, 2022
Chlamydia Infections – Pipeline by Evofem Biosciences Inc, 2022
Chlamydia Infections – Pipeline by Genetic Immunity Inc, 2022
Chlamydia Infections – Pipeline by Lead Discovery Center GmbH, 2022
Chlamydia Infections – Pipeline by Merck & Co Inc, 2022
Chlamydia Infections – Pipeline by Microbiotix Inc, 2022
Chlamydia Infections – Pipeline by QureTech Bio AB, 2022
Chlamydia Infections – Pipeline by Sanofi, 2022
Chlamydia Infections – Pipeline by Traccine Pharmaceuticals, 2022
Chlamydia Infections – Pipeline by Vault Pharma Inc, 2022
Chlamydia Infections – Pipeline by Vaxine Pty Ltd, 2022
Chlamydia Infections – Pipeline by Yaso Therapeutics Inc, 2022
Chlamydia Infections – Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chlamydia Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Chlamydia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CA2F683F8B8AEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA2F683F8B8AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

